
|Videos|December 13, 2021
Expert: Chronic Lymphocytic Leukemia Can Effect Younger Individuals
Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals
Advertisement
In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).
He discussed how common CLL is for younger individuals.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
4
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
5




























































































































